The ATIC-led IAA trial has commenced in Melbourne, with clinical trial centres to open in Adelaide, Perth, Brisbane and Sydney.
Drive the implementation of immunotherapy clinical trials throughout Australia and New Zealand
Work closely with the type 1 diabetes community across the research cycle, from trial development through recruitment to communication of...
Harmonise data collection and ensure linkage with national and international diabetes networks.
Train, equip and update clinicians, scientists and the wider community on the fundamentals of immunotherapy, as well as the latest...
Attract immunotherapy trials to Australasia through innovation: the discovery of improved biomarkers, development of new therapies, and facilitation of biosample...
The next seminar in our Beyond Insulin series will take place Thursday the 23rd of March from 1pm – 2pm. Dr Aveni Haynes will present her research using continuous glucose monitoring devices, which measure sugar levels in the body every 5 minutes for up to 10 days in a row, to investigate how and when sugar patterns change during the early stages of type 1 diabetes, in very young children at risk, before any symptoms or signs of the condition.
The human immune system works every minute of every day to keep the body healthy – through constant monitoring, and by tracking and destroying pathogens, such as disease-causing bacteria and viruses.
ATIC recently invited members of the type 1 diabetes community to learn more about ATIC – the first Australasian clinical trial collaborative set up to accelerate development and delivery of immunotherapy treatments for people with type 1 diabetes.
5th seminar in the ‘Beyond Insulin: Innovative research in T1D prevention and cure’ seminar series